These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 37455272)

  • 21. Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines?
    Ho NI; Huis In 't Veld LGM; Raaijmakers TK; Adema GJ
    Front Immunol; 2018; 9():2874. PubMed ID: 30619259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants.
    Hanson MC; Crespo MP; Abraham W; Moynihan KD; Szeto GL; Chen SH; Melo MB; Mueller S; Irvine DJ
    J Clin Invest; 2015 Jun; 125(6):2532-46. PubMed ID: 25938786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Norovirus (NoV) specific protective immune responses induced by recombinant P dimer vaccine are enhanced by the mucosal adjuvant FlaB.
    Verma V; Tan W; Puth S; Cho KO; Lee SE; Rhee JH
    J Transl Med; 2016 May; 14(1):135. PubMed ID: 27184355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of Cytotoxic T-Lymphocyte Responses Upon Subcutaneous Administration of a Subunit Vaccine Adjuvanted With an Emulsion Containing the Toll-Like Receptor 3 Ligand Poly(I:C).
    Schmidt ST; Pedersen GK; Neustrup MA; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
    Front Immunol; 2018; 9():898. PubMed ID: 29760705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current Developments and Challenges of mRNA Vaccines.
    Chen J; Chen J; Xu Q
    Annu Rev Biomed Eng; 2022 Jun; 24():85-109. PubMed ID: 35231177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modular platforms for the assembly of self-adjuvanting lipopeptide-based vaccines for use in an out-bred population.
    Zeng W; Horrocks KJ; Tan ACL; Wong CY; Chua BY; Jackson DC
    Vaccine; 2020 Jan; 38(3):597-607. PubMed ID: 31740096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod.
    Othoro C; Johnston D; Lee R; Soverow J; Bystryn JC; Nardin E
    Infect Immun; 2009 Feb; 77(2):739-48. PubMed ID: 19047411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses.
    Seydoux E; Liang H; Dubois Cauwelaert N; Archer M; Rintala ND; Kramer R; Carter D; Fox CB; Orr MT
    J Immunol; 2018 Jul; 201(1):98-112. PubMed ID: 29769270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TLR9 and STING agonists cooperatively boost the immune response to SARS-CoV-2 RBD vaccine through an increased germinal center B cell response and reshaped T helper responses.
    Yang JX; Tseng JC; Tien CF; Lee CY; Liu YL; Lin JJ; Tsai PJ; Liao HC; Liu SJ; Su YW; Hsu LC; Chen JK; Huang MH; Yu GY; Chuang TH
    Int J Biol Sci; 2023; 19(9):2897-2913. PubMed ID: 37324951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route.
    Lombardi V; Van Overtvelt L; Horiot S; Moussu H; Chabre H; Louise A; Balazuc AM; Mascarell L; Moingeon P
    Clin Exp Allergy; 2008 Nov; 38(11):1819-29. PubMed ID: 18644025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.
    Moreno Ayala MA; Gottardo MF; Gori MS; Nicola Candia AJ; Caruso C; De Laurentiis A; Imsen M; Klein S; Bal de Kier Joffé E; Salamone G; Castro MG; Seilicovich A; Candolfi M
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1713-1732. PubMed ID: 28432455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity.
    Seya T; Shime H; Takeda Y; Tatematsu M; Takashima K; Matsumoto M
    Cancer Sci; 2015 Dec; 106(12):1659-68. PubMed ID: 26395101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
    Cluff CW
    Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccine adjuvants to engage the cross-presentation pathway.
    Lee W; Suresh M
    Front Immunol; 2022; 13():940047. PubMed ID: 35979365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intradermal administration of the Type II heat-labile enterotoxins LT-IIb and LT-IIc of enterotoxigenic Escherichia coli enhances humoral and CD8+ T cell immunity to a co-administered antigen.
    Hu JC; Mathias-Santos C; Greene CJ; King-Lyons ND; Rodrigues JF; Hajishengallis G; Ferreira LC; Connell TD
    PLoS One; 2014; 9(12):e113978. PubMed ID: 25536061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
    Yu C; An M; Li M; Liu H
    Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel lipopeptides of ESAT-6 induce strong protective immunity against Mycobacterium tuberculosis: Routes of immunization and TLR agonists critically impact vaccine's efficacy.
    Gupta N; Vedi S; Kunimoto DY; Agrawal B; Kumar R
    Vaccine; 2016 Nov; 34(46):5677-5688. PubMed ID: 27693020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
    Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
    Front Immunol; 2021; 12():786144. PubMed ID: 35095862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pam2CSK4-adjuvanted SARS-CoV-2 RBD nanoparticle vaccine induces robust humoral and cellular immune responses.
    Qiao Y; Zhan Y; Zhang Y; Deng J; Chen A; Liu B; Zhang Y; Pan T; Zhang W; Zhang H; He X
    Front Immunol; 2022; 13():992062. PubMed ID: 36569949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.